Dr. Errol Gordon, MD

Claim this profile

St. John Medical Center

Studies Stroke
Studies Ischemic Injury
4 reported clinical trials
6 drugs studied

Affiliated Hospitals

Image of trial facility.
St. John Medical Center
Image of trial facility.
Ascension St. John

Clinical Trials Errol Gordon, MD is currently running

Image of trial facility.

Tissue Kallikrein

for Ischemic Stroke

This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
Recruiting0 awards Phase 2 & 37 criteria
Image of trial facility.

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Recruiting1 award Phase 32 criteria

More about Errol Gordon, MD

Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Errol Gordon, MD has experience with
  • Placebo
  • Recombinant Human Tissue Kallikrein
  • Recombinant Activated Factor VII (rFVIIa)
  • Recombinant Factor VIIa
  • Argatroban
  • Eptifibatide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Errol Gordon, MD specialize in?
Is Errol Gordon, MD currently recruiting for clinical trials?
Are there any treatments that Errol Gordon, MD has studied deeply?
What is the best way to schedule an appointment with Errol Gordon, MD?
What is the office address of Errol Gordon, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security